Precautions and daily monitoring requirements for taking momelotinib

While taking molotinib (Momelotinib), patients first need to pay special attention to their liver and kidney function. The drug is a JAK1/JAK2 inhibitor and can improve anemia and splenomegaly in patients with myelofibrosis, but it may also put some pressure on liver function. Therefore, it is necessary to regularly detect ALT, AST, bilirubin and other indicators before medication and during treatment, so as to detect abnormalities as early as possible. In addition, if the patient has moderate to severe renal insufficiency, it should be used with caution after a doctor's evaluation, and the dosage or monitoring frequency should be adjusted according to the specific situation.

Hematology monitoring is another key component of molotinib treatment. Due to its potential risk of affecting blood cell production, some patients may experience changes in white blood cells, hemoglobin or platelet levels. Therefore, it is recommended to review blood routine every 2–4 weeks at the beginning of treatment. After stabilization, the monitoring interval can be appropriately extended. If there are obvious signs of worsening anemia or increased risk of infection, you should promptly communicate with your doctor to adjust the plan. At the same time, for patients with chronic inflammation or immune abnormalities, active infection needs to be ruled out before starting treatment to avoid aggravation of the condition due to immune regulation.

In daily life, patients should avoid contact with factors that may increase the risk of bleeding and infection, such as avoiding violent collisions, not taking anticoagulants or non-steroidal anti-inflammatory drugs at will, and maintain good hygiene and nutritional status. Some patients may experience gastrointestinal discomfort, headache or fatigue during treatment, usually mild to moderate, but if symptoms persist or worsen suddenly, they should seek medical attention in time. In addition, since molotinib has not yet been launched in China and is mostly obtained through overseas channels, patients must choose regular and reliable sources when obtaining the drug to ensure drug quality and stability.

Finally, patients should closely record changes in their symptoms during the entire course of treatment, including improvement in anemia, reduction in spleen discomfort, changes in physical strength, etc., so that doctors can evaluate the treatment response and decide whether to continue, adjust the dose, or change the regimen. At the same time, you should not increase or decrease the dosage or interrupt the medication on your own to avoid affecting the efficacy or causing recurrence of the condition. Taken together, good monitoring, standardized medication behavior, and continuous communication with doctors are the keys to ensuring the safety and effectiveness of molotinib treatment.

Reference materials:https://www.fda.gov/